Recent studies have reported that the overall survival of patients with EGFR-mutated advanced NSCLC was up to 38.6 months after osimertinib treatment, and postoperative adjuvant therapy with osimertinib significantly increased disease-free survival [6, 7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.